Dar Al Dawa Development and Investment Valuation

Is DADI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DADI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DADI (JOD1.25) is trading above our estimate of fair value (JOD0.26)

Significantly Below Fair Value: DADI is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DADI?

Key metric: As DADI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DADI. This is calculated by dividing DADI's market cap by their current earnings.
What is DADI's PE Ratio?
PE Ratio	13.1x
Earnings	د.أ3.35m
Market Cap	د.أ43.75m

DADI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	8.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does DADI's PE Ratio compare to its peers?

The above table shows the PE ratio for DADI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	15x
HPIC Hayat Pharmaceutical Industries	8.5x	n/a	د.أ24.9m
PHIL Philadelphia Pharmaceuticals	12.5x	n/a	د.أ10.5m
524500 Kilitch Drugs (India)	30.1x	n/a	₹5.0b
1J5 Hyphens Pharma International	8.8x	6.7%	S$91.1m
DADI Dar Al Dawa Development and Investment	13.1x	n/a	د.أ43.8m

Price-To-Earnings vs Peers: DADI is good value based on its Price-To-Earnings Ratio (13.1x) compared to the peer average (15x).

Price to Earnings Ratio vs Industry

How does DADI's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

13 Companies	Price / Earnings	Estimated Growth	Market Cap

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: DADI is good value based on its Price-To-Earnings Ratio (13.1x) compared to the Asian Pharmaceuticals industry average (24.7x).

Price to Earnings Ratio vs Fair Ratio

What is DADI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DADI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DADI's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.